Investigational Drug Details
| Drug ID: | D303 |
| Drug Name: | Rifampicin |
| Synonyms: | 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; RFP; Rifampicin; Rifampin |
| Type: | Chemical drug |
| DrugBank ID: | DB01045 |
| DrugBank Description: | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) |
| PubChem ID: | 135398735 |
| CasNo: | 13292-46-1 |
| Repositioning for NAFLD: | Yes |
| SMILES: | Oc1c2c3c4O[C@](C3=O)(C)O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(=O)C)[C@H](C)[C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(\C(=O)Nc(c1/C=N/N1CCN(CC1)C)c(c2c(c4C)O)O)/C)C)O)C)O |
| Structure: |
|
| InChiKey: | JQXXHWHPUNPDRT-WLSIYKJHSA-N |
| Molecular Weight: | 822.953 |
| DrugBank Targets: | DNA-directed RNA polymerase subunit beta inhibitor; Nuclear receptor subfamily 1 group I member 2 agonist |
| DrugBank MoA: | Rifampin acts via the inhibition of DNA-dependent RNA polymerase, leading to a suppression of RNA synthesis and cell death. |
| DrugBank Pharmacology: | Rifampin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including <i>Pseudomonas aeruginosa</i>) and specifically <i>Mycobacterium tuberculosis</i>. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifampin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency. |
| DrugBank Indication: | For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections. |
| Targets: | NR1I2 agonist |
| Therapeutic Category: | Antimycobacterial drug |
| Clinical Trial Progress: | Phase 4 completed (NCT02329405) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0096 | NCT02329405 | Phase 4 | Completed | No Results Available | December 2014 | November 1, 2017 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00494 | 35062050 | Biomed Pharmacother | CYP450 drug inducibility in NAFLD via an in vitro hepatic model: Understanding drug-drug interactions in the fatty liver. | Details |
| A05416 | 33268331 | Biol Open | iPSC-derived hepatocytes generated from NASH donors provide a valuable platform for disease modeling and drug discovery. | Details |
| A21933 | 24955981 | Biochem Pharmacol | LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver. | Details |
| A26623 | 20079722 | Chem Biol Interact | Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. | Details |
| A45821 | 22531045 | Drug Metab Dispos | In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties. | Details |
| A48914 | 24710571 | Arch Toxicol | LC-MS-based metabolomics: an update. | Details |
| A51315 | 35677517 | J Clin Exp Hepatol | Extrapulmonary Tuberculosis in Cirrhosis: Too Familiar-Too Much Unknown. | Details |